[Positive Effects of Perindopril on Microvascular Vessels in Patients With Chronic Heart Failure].


Journal

Kardiologiia
ISSN: 0022-9040
Titre abrégé: Kardiologiia
Pays: Russia (Federation)
ID NLM: 0376351

Informations de publication

Date de publication:
17 Sep 2020
Historique:
received: 05 06 2020
accepted: 30 06 2020
entrez: 6 11 2020
pubmed: 7 11 2020
medline: 11 11 2020
Statut: epublish

Résumé

Aim      To evaluate the effect of 12-month perindopril treatment on structure and function of microvasculature (MV) in patients with chronic heart failure with preserved (HFpEF) and intermediate (HFiEF) left ventricular ejection fraction.Material and methods  30 patients with HFpEF and HFiEF were evaluated. Perindopril at a maximum tolerated dose was administered to all patients for 12 months. Changes in MV structure and function were assessed with photoplethysmography and capillaroscopy prior to the treatment onset and at 12 months, i.e., after completion of the perindopril treatment.Results The 12-month perindopril treatment was associated with improvement of the endothelial function evident as increases in the occlusion index (OI) and the phase shift (PS). OI increased from 1.45 [1.3; 1.6] to 1.8 [1.6; 2.2] (p=0.00004). PS increased from 7.1 ms [4.8; 10.2] to 9.2 ms [6.7; 13.2] (p=0.0003). Stiffness of muscular large blood vessels was decreased. Arterial stiffness index (aSI) decreased from 8.8 [6.6; 11.0] to 7.45 [6.5; 9.4] m /s (р=0.01). The perindopril treatment was associated with increased density of the capillary network at rest (р=0.008) and in tests with venous occlusion (р=0.003) and reactive hyperemia (р=0.0003).Conclusion      The study showed an improvement of endothelial function associated with the 12-month perindopril therapy in patients with HFpEF and HFiEF.

Identifiants

pubmed: 33155960
doi: 10.18087/cardio.2020.8.n1216
doi:

Substances chimiques

Perindopril Y5GMK36KGY

Types de publication

Journal Article

Langues

rus

Sous-ensembles de citation

IM

Pagination

65-70

Auteurs

J I Safonova (JI)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

M V Kozhevnikova (MV)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

Yu A Danilogorskaya (YA)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

E A Zheleznykh (EA)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

V Y Zektser (VY)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

A A Shchendrygina (AA)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

I S Ilgisonis (IS)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

E V P (EV)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

N V Khabarova (NV)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

Yu N Belenkov (YN)

Sechenov First Moscow State Medical University (Sechenov University), Moscow.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH